New hope for blistering skin diseases: drug targets antibodies to heal wounds

NCT ID NCT07011589

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA). About 18 participants aged 12 and older will receive the drug intravenously, and those with RDEB will also receive a topical gene therapy (VYJUVEK) on one wound. The goal is to see if reducing these antibodies leads to fewer wounds and better quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired epidermolysis bullosa dystrophic epidermolysis bullosa, dog epidermolysis bullosa epidermolysis bullosa dystrophica recessive dystrophic epidermolysis bullosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    Redwood City, California, 94163, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact